Assessing agonistic potential of a candidate therapeutic anti-IL21R antibody.

about

Development and application of a biomarker assay for determining the pharmacodynamic activity of an antagonist candidate biotherapeutic antibody to IL21R in whole blood.

P2860

Q41468161-F06FD871-322C-4669-A7A7-8B8B7B96E9C7

P2860

Assessing agonistic potential of a candidate therapeutic anti-IL21R antibody.

Item

http://www.wikidata.org/entity/Q39700129

description

2010 nî lūn-bûn

@nan

2010年の論文

@ja

2010年学术文章

@wuu

2010年学术文章

@zh-cn

2010年学术文章

@zh-hans

2010年学术文章

@zh-my

2010年学术文章

@zh-sg

2010年學術文章

@yue

2010年學術文章

@zh

2010年學術文章

@zh-hant

name

Assessing agonistic potential of a candidate therapeutic anti-IL21R antibody.

@en

Assessing agonistic potential of a candidate therapeutic anti-IL21R antibody.

@nl

type

Item

label

Assessing agonistic potential of a candidate therapeutic anti-IL21R antibody.

@en

Assessing agonistic potential of a candidate therapeutic anti-IL21R antibody.

@nl

prefLabel

Assessing agonistic potential of a candidate therapeutic anti-IL21R antibody.

@en

Assessing agonistic potential of a candidate therapeutic anti-IL21R antibody.

@nl

P1476

Assessing agonistic potential of a candidate therapeutic anti-IL21R antibody.

@en

P2093

Andrew A Hill

http://www.w3.org/2001/XMLSchema#string

Christopher Corcoran

http://www.w3.org/2001/XMLSchema#string

Deborah Young

http://www.w3.org/2001/XMLSchema#string

Edward R Lavallie

http://www.w3.org/2001/XMLSchema#string

Frederick W Immermann

http://www.w3.org/2001/XMLSchema#string

Garvin Warner

http://www.w3.org/2001/XMLSchema#string

Laird Bloom

http://www.w3.org/2001/XMLSchema#string

Marcia Bologna

http://www.w3.org/2001/XMLSchema#string

Margot O'Toole

http://www.w3.org/2001/XMLSchema#string

Mark Ryan

http://www.w3.org/2001/XMLSchema#string

P2860

Interleukin 21 and its receptor are involved in NK cell expansion and regulation of lymphocyte function

Analysis of Relative Gene Expression Data Using Real-Time Quantitative PCR and the 2−ΔΔCT Method

IL-21 is produced by NKT cells and modulates NKT cell activation and cytokine production

Involvement of p72syk, a protein-tyrosine kinase, in Fc gamma receptor signaling

IgG Fc receptors

IL-21 initiates an alternative pathway to induce proinflammatory T(H)17 cells

Cytokine storm in a phase 1 trial of the anti-CD28 monoclonal antibody TGN1412

Correlation of pharmacodynamic activity, pharmacokinetics, and anti-product antibody responses to anti-IL-21R antibody therapeutics following IV administration to cynomolgus monkeys

In vitro potency, pharmacokinetic profiles, and pharmacological activity of optimized anti-IL-21R antibodies in a mouse model of lupus

IL-21 signaling is critical for the development of type I diabetes in the NOD mouse.

P2888

1479-5876-8-50

P304

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1186/1479-5876-8-50

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P577

2010-05-26T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

44632076

http://www.w3.org/2001/XMLSchema#string

P6179

1021138082

http://www.w3.org/2001/XMLSchema#string

P698

20504348

http://www.w3.org/2001/XMLSchema#string

P932

2896924

http://www.w3.org/2001/XMLSchema#string

Assessing agonistic potential of a candidate therapeutic anti-IL21R antibody.

about

P2860

P2860

Assessing agonistic potential of a candidate therapeutic anti-IL21R antibody.

description

name

type

label

prefLabel

P1433

P1476

P2093

P2860

P2888

P304

P31

P356

P478

P577

P5875

P6179

P698

P932

P356

P1433

P1476

P2093

P2860

P2888

P304

P31

P356

P478

P577

P5875

P6179

P698

P932